A. Hojo

发表

Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma

M. Takei, N. Iriyama, Y. Hatta, 2014, Leukemia & lymphoma.

A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation

Y. Hatta, J. Takeuchi, Sumiko Kobayashi, 2010, International journal of hematology.

Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.

N. Iriyama, Y. Hatta, Machiko Kusuda, 2013, Oncology Report.

An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

N. Iriyama, Y. Hatta, J. Takeuchi, 2011, International journal of hematology.

A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior

M. Takei, K. Ohshima, N. Iriyama, 2016, Virchows Archiv.

Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies

M. Takei, N. Iriyama, Y. Hatta, 2016, International Journal of Hematology.

Positive Expression of Macrophage Inflammatory Protein-1α and -1β in a Patient with Diffuse Large B-cell Lymphoma Accompanied by Hypercalcemia and Multiple Osteolysis

S. Aizawa, Y. Hatta, J. Takeuchi, 2011 .

Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.

M. Takei, Y. Kanda, Y. Hatta, 2016, Cancer genetics.

Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma

M. Takei, N. Iriyama, Y. Hatta, 2015, International Journal of Hematology.

Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP.

N. Iriyama, Y. Hatta, J. Takeuchi, 2012, Experimental and therapeutic medicine.

Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma

N. Iriyama, Y. Hatta, J. Takeuchi, 2011, Journal of Cancer Research and Clinical Oncology.

Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy

M. Takei, N. Iriyama, Y. Hatta, 2016, Leukemia & lymphoma.

Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy

M. Takei, T. Nakayama, N. Iriyama, 2016, Leukemia & lymphoma.

Title : Clinical significance of co-expression of MYC and BCL 2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy Running title : MYC / BCL 2 in relapse / refractory lymphomas

M. Takei, N. Iriyama, Y. Hatta, 2015 .

A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.

Y. Hatta, Y. Maeda, J. Takizawa, 2017, The oncologist.

Attenuated immunochemotherapy for diffuse large B-cell lymphoma.

Y. Hatta, J. Takeuchi, K. Miura, 2011, The Lancet. Oncology.

A case of fulminant Clostridium perfringens infection: Role of macroscopic examination of the serum and peripheral blood smears

R. Kogawa, Y. Uehara, U. Sawada, 2021, IDCases.

Dose-Intensified CHOP with Rituximab (R-Double-CHOP) Followed by Consolidating High-Dose Chemotherapy Is An Effective Treatment for Younger Patients with Advanced Diffuse Large B-Cell Lymphoma

N. Iriyama, Y. Hatta, J. Takeuchi, 2011 .

A case series of Bacillus cereus septicemia in patients with hematological disease.

N. Iriyama, Y. Hatta, J. Takeuchi, 2012, Internal medicine.